The organization said the vaccine's efficacy was 87.5%, compared to 89.8% in the main study.
The organization released the results from a sub-study it conducted as a part of its late-stage clinical test of NVX-CoV2373, its protein-based Covid-19 vaccine candidate, within the uk .
The 431 participants enrolled within the sub-study received an approved seasonal influenza vaccine with about half the participants administered NVX-CoV2373, while the remainder received placebo.
President of research and development at Novavax,Gregory Glenn said "... these results demonstrate the promising opportunity for concomitant vaccination, which can improve the uptake of both vaccines" .
Novavax is additionally testing its combined flu/Covid-19 vaccine and in May said the mixture produced functional antibodies against influenza and therefore the coronavirus during a pre-clinical study.
